相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping A Phase 2 Randomized Clinical Trial
Paula R. Clemens et al.
JAMA NEUROLOGY (2020)
Therapeutic developments for Duchenne muscular dystrophy
Ingrid E. C. Verhaart et al.
NATURE REVIEWS NEUROLOGY (2019)
Dystrophin restoration by exon 53 skipping in patients with Duchenne muscular dystrophy after viltolarsen treatment: phase 2 study update
P. Clemens et al.
NEUROMUSCULAR DISORDERS (2019)
Systemic administration of the antisense oligonucleotide NS-065/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy
Hirofumi Komaki et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
NS-065/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy
Naoki Watanabe et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2018)
Pharmacological advances for treatment in Duchenne muscular dystrophy
Simon Guiraud et al.
CURRENT OPINION IN PHARMACOLOGY (2017)
Antisense Therapy in Neurology
Joshua J. A. Lee et al.
JOURNAL OF PERSONALIZED MEDICINE (2013)
分享论文
